James Paul Lang

James Paul Lang, listed as board member, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in OptimizeRx Corp, Biovie Inc. and Halozyme Therapeutics, Inc. We count 11 filings; the first trade dates from 30 June 2021 and the latest from 2 January 2026.

Purchases make up the whole of the open-market record (2 purchases, €2.3M). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants and 5 option exercises.

The newest entry dates from 6 January 2026: a share grant, in Halozyme Therapeutics, Inc. The last purchase on record was published on 19 March 2025, which is 578 days ago. The median gap between a trade and its publication by SEC (Form 4) is 5 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.